Basle, Switzerland, June 11, 2018. Memo Therapeutics AG announces that Dr. Karsten Fischer was appointed as Chief Executive Officer of the company effective June 01, 2018.

Dr. Fischer will lead the company as its orientation shifts from technological excellence towards pharma partnerships and product development. Founder and former interim CEO, Dr. Christoph Esslinger will focus his efforts as Chief Scientific Officer on the continued advancement of the MemoMAB platform and on the expansion of MEMO’s proprietary antibody discovery programs in immune-oncology and infectious diseases.

Prior to joining MEMO, Dr. Fischer was a partner of BioMedPartners AG and invested in several successful companies in the life science field. Before that, Dr. Fischer has been working for WestLB on equity, M&A, and debt transactions in the healthcare and chemicals sector. Moreover, he has a track record in management consulting with McKinsey and pharmaceutical sales&marketing with Sanofi. He holds a Ph.D. in infection biology (MPI Infection Biology and Colorado State University, with distinction).

“Memo is poised to establish its MemoMAB technology as a world leading platform for antibody discovery and has developed a highly promising pipeline. I am very much looking forward to help the company to manage the next evolutionary step and on bringing its strong value proposition into partnerships and its own pipeline” said Karsten Fischer.

Dr. Peter Burckhardt, Chairman of the Memo Supervisory Board, commented: “As we look to the next phase of growth for Memo, we are very pleased to have been able to recruit Karsten to develop the company to become a major player in the field of therapeutic antibody discovery and development.”